BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

CorestemChemon Phase 3 ALSummit Trial Shows Subgroup Benefit of Neuronata-R® in ALS

CorestemChemon Inc. announced that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel) an autolo...

September 22, 2025 | News

Lenovo Launches GOAST v4.0 Slashing Genome Analysis to 24 Minutes with 3x Higher Throughput

Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries Lenovo shared updates ...

September 22, 2025 | News

Alnylam Joins Illumina and NashBio’s Alliance for Genomic Discovery

Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members levera...

September 19, 2025 | News

Mikart and Nano PharmaSolutions Report Positive Phase 1 Data for NT-301 in Parkinson’s Disease

Mikart, LLC, a leading contract development and manufacturing organization (CDMO), and Nano PharmaSolutions, Inc. (NPS), a nanodrug delivery pharmaceutical...

September 19, 2025 | News

Ono Pharmaceutical Wins EU Approval for Vimseltinib as First TGCT Therapy

Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co., a...

September 19, 2025 | News

Kexing Biopharm Completes FDA Type II DMF Registration for Stem Cell-Derived Exosomes

Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Ma...

September 18, 2025 | News

WuXi Biologics Secures First Turkish GMP Certification for Three Facilities

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturin...

September 18, 2025 | News

Mabwell and Aditum Bio Launch Kalexo Bio with $1 Billion siRNA Deal for Dyslipidemia and ASCVD

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio announced the launch of Kalexo Bio, a new company formed in conjunction with an exc...

September 18, 2025 | News

Skyhawk’s SKY-0515 Shows 62% Reduction in Mutant Huntingtin at Day 84 in Huntington’s Disease Trial

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose Additional finding...

September 18, 2025 | News

Eli Lilly to Invest $5 Billion in New Virginia API and Bioconjugate Manufacturing Facility

New site in Virginia's Goochland County will develop active pharmaceutical ingredients (API) in the U.S. for cancer, autoimmune and other ad...

September 17, 2025 | News

US, China and Australia Begin Phase 2 Trial of Atom Therapeutics’ ABP-745 for Acute Gout Flares

ABP-745 is an oral small molecule drug with potential applications, for other inflammatory conditions such as cardiovascular disease Atom T...

September 17, 2025 | News

China’s Biocytogen Licenses Fully Human Antibody to Tubulis for Novel ADC Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel ...

September 17, 2025 | News

ProBioGen to Operate GMP Manufacturing Hub at Berlin’s New Gene and Cell Therapy Centre

ProBioGen and the Berlin Institute of Health at Charité (BIH) announced that ProBioGen has been selected to operate the process...

September 17, 2025 | News

Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate

Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...

September 16, 2025 | News

Stay Connected